Free Trial Information
BioCentury | Mar 24, 2017
Company News

Critical Path biomarker consortium

...receptor type N ( PTPRN ; ICA512 ; IA2) and solute carrier family 30 zinc transporter member 8 ( SLC30A8 ; ZNT8...
Read More
BioCentury | Mar 21, 2017
Politics & Policy

C-PATH consortium seeks to qualify diabetes biomarkers

...receptor type N ( PTPRN ; ICA512 ; IA2) and solute carrier family 30 zinc transporter member 8 ( SLC30A8 ; ZNT8...
Read More
BioCentury | Sep 1, 2014
Clinical News

ZnT8Ab ELISA Assay regulatory update

...assay detects the autoantibody against solute carrier family 30 zinc-transporter member 8 ( SLC30A8 ; ZNT8...
Read More
BioCentury | Aug 21, 2014
Company News

FDA approves Kronus' Type I diabetes test

...assay detects the autoantibody against solute carrier family 30 zinc-transporter member 8 ( SLC30A8 ; ZNT8...
Read More
BioCentury | Mar 13, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...and contact information Endocrine/metabolic disease Diabetes Solute carrier family 30 zinc transporter member 8 (SLC30A8; ZNT8) Human genetic studies suggest inhibiting SLC30A8...
...or treat type 2 diabetes. Previous studies in mice had alternatively suggested that loss of SLC30A8...
...2 diabetes. Genotyping and analysis of about 150,000 individuals showed that carriers of mutations in SLC30A8...
Read More
BioCentury | Mar 13, 2014
Targets & Mechanisms

Zinc-ing about diabetes

...studies are needed to flesh out the functional consequences of expression of ZNT8 (solute carrier family 30 zinc transporter member 8; SLC30A8...
...multiple population cohorts identified 12 different ZNT8 variants that encoded a truncated version of the ZNT8...
...how the phenotype compares with that of human carriers of the protective ZNT8 variants. Homozygous Znt8...
Read More
BioCentury | Oct 17, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...information Endocrine/metabolic disease Diabetes Solute carrier family 30 zinc transporter member 8 (SLC30A8; ZNT8) Mouse and human studies suggest stimulating pancreatic SLC30A8...
...Mouse and human studies suggest stimulating pancreatic SLC30A8 could help treat diabetes. Humans with the SLC30A8...
...have an elevated risk of developing type 2 diabetes. In mice, b cell-specific knockout of Slc30a8...
Read More
BioCentury | Jun 18, 2001
Top Story

Zentaris pulls IPO

Following last week's downturn in the Neuer Markt, oncology and endocrinology play Zentaris (Proposed-NMarkt:ZNT) postponed its IPO. The company, which is being spun out of Asta Medica, was offering 6 million shares at EUR11-EUR14 and...
Read More
BioCentury | Jun 11, 2001
Finance

Ebb & Flow

Cor Therapeutics' decision to pad its coffers with $250 million via convertible notes had the M&A rumor mill abuzz last week. Scuttlebutt largely centered on the company's prospects for putting a second product into the...
Read More
Items per page:
1 - 9 of 9